Literature DB >> 11376422

Radiolabeled sentinel node biopsy: collaborative trial with the National Cancer Institute.

D N Krag1, S Harlow, D Weaver, T Ashikaga.   

Abstract

The objective of this study was to maximize the success rate of sentinel node (SN) localization in breast cancer patients with the tracer that demonstrated the highest initial success during a preliminary evaluation. Altogether, 145 patients with operable invasive breast cancer and clinically negative lymph nodes were studied. Technetium 99m (99mTc)-sulfur colloid was injected into the breast parenchyma surrounding the invasive cancer or the biopsy cavity. Variable volumes of tracer, amounts of 99mTc, and duration of time between injection and surgery were evaluated. A hand-held gamma detector was used at surgery to locate and guide resection of all radioactive sentinel nodes (SNs), including those that were extraaxillary. A conventional lymphadenectomy was then performed in all cases. Based on previous studies, unfiltered sulfur colloid provided a higher success rate of SN identification than the other tracer types. Further evaluation with 99mTc-sulfur colloid demonstrated that increased volume increased the success rate of SN identification. An injection volume of 8 ml resulted in a success rate of 98%. SNs were not exclusively located in the axilla: In 8.6% of cases SNs were removed from an internal mammary location. The overall accuracy of patients with SNs resected was 98.4%, and the false-negative rate was 4.4%. It was concluded that (1) unfiltered 99mTc-sulfur colloid at a volume of 8 ml resulted in a high success rate for SN identification; (2) a significant number of the SNs were extraaxillary in location; and (3) the accuracy of the SNs for determining whether regional metastases had occurred was high. The U.S. National Cancer Institute is funding a randomized phase III clinical trial to evaluate SN resection compared to conventional axillary lymphadenectomy in clinical node-negative breast cancer patients. Major endpoints of this trial include long-term regional control and survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376422     DOI: 10.1007/s00268-001-0012-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  4 in total

1.  A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy.

Authors:  Jason David Cundiff; Yi-Zarn Wang; Gregory Espenan; Thomas Maloney; Arthur Camp; Laura Lazarus; Alan Stolier; Randy Brooks; Bruce Torrance; Shawn Stafford; James P O'Leary; Eugene A Woltering
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

3.  Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid - a single institution Indian experience.

Authors:  S P Somashekhar; S Zaveri Shabber; K Udupa Venkatesh; K Venkatachala; M M Vasan Thirumalai
Journal:  Indian J Surg       Date:  2008-07-24       Impact factor: 0.656

4.  The impact of previous para-areolar incision in the upper outer quadrant of the breast on the localization of the sentinel lymph node in a canine model.

Authors:  Paulo Henrique Diógenes Vasques; Luiz Gonzaga Porto Pinheiro; João Marcos de Meneses E Silva; José Ricardo de Moura Torres-de-Melo; Karine Bessa Porto Pinheiro; João Ivo Xavier Rocha
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.